Literature DB >> 9685230

Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.

R L Rosati1, P Da Silva Jardine, K O Cameron, D D Thompson, H Z Ke, S M Toler, T A Brown, L C Pan, C F Ebbinghaus, A R Reinhold, N C Elliott, B N Newhouse, C M Tjoa, P M Sweetnam, M J Cole, M W Arriola, J W Gauthier, D T Crawford, D F Nickerson, C M Pirie, H Qi, H A Simmons, G T Tkalcevic.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685230     DOI: 10.1021/jm980048b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  21 in total

1.  Kinetic analysis of estrogen receptor/ligand interactions.

Authors:  Rebecca L Rich; Lise R Hoth; Kieran F Geoghegan; Thomas A Brown; Peter K LeMotte; Samuel P Simons; Preston Hensley; David G Myszka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

2.  The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.

Authors:  Kaitlyn J Andreano; Jennifer G Baker; Sunghee Park; Rachid Safi; Sandeep Artham; Steffi Oesterreich; Rinath Jeselsohn; Myles Brown; Sarah Sammons; Suzanne E Wardell; Ching-Yi Chang; John D Norris; Donald P McDonnell
Journal:  Mol Cancer Ther       Date:  2020-05-07       Impact factor: 6.261

Review 3.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 4.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

Review 5.  Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

Authors:  Jing Peng; Surojeet Sengupta; V Craig Jordan
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

6.  Lasofoxifene: Evidence of its therapeutic value in osteoporosis.

Authors:  Luigi Gennari; Daniela Merlotti; Vincenzo De Paola; Ranuccio Nuti
Journal:  Core Evid       Date:  2010-06-15

Review 7.  Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.

Authors:  Luigi Gennari; Daniela Merlotti; Ranuccio Nuti
Journal:  Clin Interv Aging       Date:  2010-02-02       Impact factor: 4.458

8.  The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.

Authors:  Felix F Vajdos; Lise R Hoth; Kieran F Geoghegan; Samuel P Simons; Peter K LeMotte; Dennis E Danley; Mark J Ammirati; Jayvardhan Pandit
Journal:  Protein Sci       Date:  2007-05       Impact factor: 6.725

9.  Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method.

Authors:  Susie Y Dai; Michael J Chalmers; John Bruning; Kelli S Bramlett; Harold E Osborne; Chahrzad Montrose-Rafizadeh; Robert J Barr; Yong Wang; Minmin Wang; Thomas P Burris; Jeffrey A Dodge; Patrick R Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-12       Impact factor: 11.205

10.  Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.